

| | | |
|----------------|-----------|----------|
| APPROVED BY | O.G. FIG. | |
| | CLASS | SUBCLASS |
| DRAFTSMAN | | |





Fig. 1

2/6

| | |
|-----------|----------------|
| APPROVED | O.G. FIG. |
| BY | CLASS SUBCLASS |
| DRAFTSMAN | |

**B**

0.5 ml
1 ml
2 ml
4 ml
8 ml
16 ml

PSGL1/mIgG_{2b}**Fig. 2**

Absorption capacity




Fig. 3

- PSGL1/mIgG2b+GalT+0.25 ml AB serum
- ◇--- PSGL1/mIgG2b+GalT+0.5 ml AB serum
- PSGL1/mIgG2b+GalT+1 ml AB serum
- △--- PSGL1/mIgG2b+GalT+2 ml AB serum
- ⊞--- PSGL1/mIgG2b+GalT+4 ml AB serum
- ◇--- AB serum non-abs. 4 ml
- ⊕--- PSGL1/mIgG2b+0.25 ml AB serum

| | |
|-----------------------------|----------------|
| APPROVED BY DRAFTSMAN | O.G. FIG. |
| | CLASS SUBCLASS |

SECRET 3646760

| | |
|-----------|----------------|
| APPROVED | O.G. FIG. |
| BY | CLASS SUBCLASS |
| DRAFTSMAN | |







Fig. 4

5/6

| | |
|-----------|----------|
| O.G. FIG. | |
| APPROVED | BY |
| CLASS | SUBCLASS |
| DRAFTSMAN | |



- PAEC binding, non-absorbed
- ◇···· PAEC binding, PSGL1/mIgG2b+GalT absorbed
- PAEC cytotoxicity, non-absorbed
- △--- PAEC cytotoxicity, PSGL1/mIgG2b+GalT absorbed

Fig. 5

6/6

| | | |
|----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| | CLASS | SUBCLASS |
| BY | DRAFTSMAN | |

- K562 serum-free
◇..... Raji serum-free
○..... Oink serum-free
 ---△--- Oink 10% AB serum





Fig. 6

- PAEC serum-free
◇..... PAEC + human AB serum
○..... PAEC + human AB serum abs. w. PSGL1/mIgG_{2b}
 ---△--- PAEC + human AB serum abs. w. Galα1,3Gal-subst. PSGL1/mIgG_{2b}